CSK: A Promising Drug Target and Biomarker for the Treatment of Cancer

Target Name: CSK

NCBI ID: G1445

Content of Review Report on CSK Target / Biomarker

CSK

CSK: A Promising Drug Target and Biomarker for the Treatment of Cancer

Introduction

CSK (Tyrosine-protein kinase CSK) is a protein that plays a critical role in cell signaling, particularly in the regulation of cell growth, differentiation, and survival. played a key role. The abnormal expression of CSK is closely related to the onset and development of various cancers. Therefore, CSK has become the research target of many cancer therapeutic drugs. This article will describe the role of CSK in cancer treatment and explore the clinical prospects of CSK as a potential drug target (or biomarker).

Mechanism of action of CSK

CSK is a transduction enzyme and belongs to the CSK-FAK kinase family. The main function of CSK is to phosphorylate tyrosine residues, resulting in activation of CSK-FAK kinase. CSK-FAK kinase plays a variety of biological roles in the cell cycle, including regulating cell cycle progression, cell proliferation, apoptosis, angiogenesis, etc. CSK also participates in a variety of signaling pathways, such as cell cycle, cell proliferation, apoptosis, extracellular signaling, etc. CSK is upregulated in a variety of cancers and is the target of many cancer therapeutic drug interventions.

The relationship between CSK and cancer

CSK is upregulated in a variety of cancers and is the target of many cancer therapeutic drug interventions. Studies have found that upregulation of CSK expression is closely related to the onset and development of various cancers, such as lung cancer, liver cancer, breast cancer, kidney cancer, etc. The expression level of CSK is closely related to the survival rate, disease progression and treatment response of cancer patients. Many studies have confirmed that CSK inhibitors have significant efficacy in the treatment of various cancers.

CSK as a potential drug target

As a potential drug target, CSK has multiple biological effects. CSK inhibitors can inhibit the phosphorylation of CSK, thereby inhibiting the activation of CSK-FAK kinase. CSK inhibitors can inhibit the role of CSK in tumors, thereby inhibiting the proliferation and growth of tumor cells. CSK inhibitors can also inhibit the transfer of CSK in tumor cells, thus providing new ideas for the treatment of tumor patients.

As a potential drug target, CSK has multiple biological effects. CSK inhibitors can inhibit the phosphorylation of CSK, thereby inhibiting the activation of CSK-FAK kinase. CSK

Protein Name: C-terminal Src Kinase

Functions: Non-receptor tyrosine-protein kinase that plays an important role in the regulation of cell growth, differentiation, migration and immune response. Phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs) including LCK, SRC, HCK, FYN, LYN, CSK or YES1. Upon tail phosphorylation, Src-family members engage in intramolecular interactions between the phosphotyrosine tail and the SH2 domain that result in an inactive conformation. To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. Suppresses signaling by various surface receptors, including T-cell receptor (TCR) and B-cell receptor (BCR) by phosphorylating and maintaining inactive several positive effectors such as FYN or LCK

The "CSK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CSK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets